Related Experiment Video
Updated: Jun 23, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Assessing the bioequivalence of biosimilars The Retacrit case
1Department of Pharmaceutical Sciences, Utrecht University, P.O. Box 80.082, 3508 TB Utrecht, The Netherlands. h.schellekens@uu.nl
Abstract:
This first phase of the first generation of modern biotechnology-derived protein drugs is now coming to an end with the expiration of their patents and consequently the possibility of the marketing of copies. The generic paradigm used for classical drugs cannot, however, be applied to therapeutic proteins because of their complexity. The European regulatory system issued its first comprehensive guidelines for the development of the so-called biosimilars. A number of these products have now been introduced to the European market. The case of Retacrit, one of the biosimilar epoetines, is being discussed as an example of the challenges encountered when assessing the bioequivalence of therapeutic proteins.
More Related Videos
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
05:01Assessment of DNA Double Strand Break Repair Activity Using High-throughput and Quantitative Luminescence-Based Reporter Assays
Published on: June 14, 2024
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence Data: Statistical Interpretation